Skip to main content
. 2023 Sep 28;147(2):607–626. doi: 10.1093/brain/awad327

Figure 1.

Figure 1

Distribution of neuropathological subtypes across distinct clinical presentations of nfvPPA. The figure illustrates the overlap, in terms of underlying neuropathology, between different speech-language phenotypes subsumed under the umbrella term ‘nfvPPA’. Apart from an increased frequency of PSP pathology in patients with dominant dysarthria (DD group), no other clinico-pathological correlations were observed [disregarding the progressive agrammatic aphasia (PAA) group which comprised one case only]. The vast majority of patients (28/33 = 85%) exhibited FTLD-tau (PSP, CBD, PiD, and unclassifiable 4R-tau) as primary neuropathology. AD = Alzheimer’s disease; AOS = apraxia of speech; CBD = corticobasal degeneration; FTLD = frontotemporal lobar degeneration; nfvPPA = non-fluent/agrammatic variant of primary progressive aphasia; PiD = Pick’s disease; PSP = progressive supranuclear palsy; PPAOS = primary progressive apraxia of speech; TDP-A = transactive response DNA-binding protein 43 kD type A.